233 related articles for article (PubMed ID: 2460557)
1. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
Djeu JY; Blanchard DK
Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
[TBL] [Abstract][Full Text] [Related]
4. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
5. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
Blanchard DK; Serbousek D; Djeu JY
Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
[TBL] [Abstract][Full Text] [Related]
6. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
9. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
[TBL] [Abstract][Full Text] [Related]
10. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma reduces the sensitivity of cultured and fresh human tumor cells to lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
Nat Immun Cell Growth Regul; 1988; 7(2):65-76. PubMed ID: 3137461
[TBL] [Abstract][Full Text] [Related]
12. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
13. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
14. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity.
Webb DS; Gerrard TL
J Immunol; 1990 May; 144(9):3643-8. PubMed ID: 2158515
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis.
Renkonen R; Ristimäki A; Häyry P
Eur J Immunol; 1988 Nov; 18(11):1839-42. PubMed ID: 3144455
[TBL] [Abstract][Full Text] [Related]
17. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
18. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
19. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
